Skip to content
Home
About Us
Our Science
Pegtarazimod
HIE
News
Home
About Us
Our Science
Pegtarazimod
HIE
News
Contact
Home
About Us
Our Science
Pegtarazimod
HIE
News
Home
About Us
Our Science
Pegtarazimod
HIE
News
Contact
Press Releases
Stay up to date on ReAlta’s news, scientific progress, clinical milestones, and mission to address severe inflammatory disease.
Press Release
Apr 08, 2026
ReAlta Life Sciences Closes Oversubscribed $40 Million Financing Round to Advance Pegtarazimod Phase 2 Program in Hypoxic Ischemic Encephalopathy (HIE)
Years
Years
2020
2021
2022
2023
2024
2025
2026
Press Releases
Press Releases
Press Release
Feb 16, 2021
ReAlta Life Sciences Doses First Subject In Phase 1 Healthy Volunteers Study Of RLS-0071
No posts found